TITLE: Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru

Short Title: Target trial emulation of effectiveness of hydroxychloroquine, azithromycin, ivermectin.

Authors:

Percy Soto-Becerra[1]

Carlos Culquichicón[1]

Yamilee Hurtado-Roca[1]

Roger V. Araujo-Castillo[1]

Affiliations:

(1) Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud, Lima, Peru.

Corresponding author:

Roger V. Araujo-Castillo

Av. Arenales 1302, office 310. Jesus Maria, Lima 15073, Peru.

Phone: 51(1) 265-6000 - Extension 1955

E-mail: roger.araujo@essalud.gob.pe

Financial statement:

This study was funded by the Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud – Peru.

Conflicts of interest:

The authors declared no conflicts of interest about this research.

ABSTRACT

Introduction: In Latin America, Peru is the most impacted country due to COVID-19 pandemic. Given the authorized nationwide use of hydroxychloroquine, azithromycin, and ivermectin in COVID-19 patients, we aimed to evaluate their effectiveness alone or combined to reduce 30-day mortality among COVID-19 hospitalized patients without life-threatening illness.

Methods: Design. Retrospective cohort study using electronic health records to emulate a target trial. Settings. Nationwide data of mid- and high-level complexity hospitals from the Peruvian Social Health Insurance (EsSalud) between April 1 and July 19, 2020. Participants. Patients 18 years old and above with confirmed SARS-CoV-2 by PCR, and no diagnosis of severe disease at admission. Interventions. Five treatment groups, hydroxychloroquine/chloroquine alone (HCQ), ivermectin alone (IVM), azithromycin alone (AZIT), HCQ + AZIT group, and IVM + AZIT within 48 hours of admission at doses recommended by the Peruvian Ministry of Health. Comparison. Standard of care treatment without receiving any of the mentioned drugs within 48 of admission. Outcomes: Primary outcome was all-cause mortality rate, and secondary outcomes were survival without death or ICU transfer, and survival without death or oxygen prescription. Analysis. Analysis were adjusted for confounding factors using inverse probability of treatment weighting. Propensity scores were estimated using machine learning boosting models. Weighted hazard ratios (wHR) were calculated using Cox regression

Results: Among 5683 patients, 200 received HCT, 203 IVM, 1600 AZIT, 692 HCQ + AZIT, 358 IVM + AZIT, and 2630 received standard of care. The AZIT + HCQ group was associated with 84% higher all-cause mortality hazard rate compared to standard care (wHR=1.84, 95%CI 1.12-3.02). Consistently, AZIT + HCQ treatment was associated with deaths or ICU transfer ICU (wHR=1.49, 95%CI 1.01-2.19), and deaths or oxygen prescription (wHR=1.70, 95%CI 1.07-2.69). HCQ treatment was only associated with death or oxygen prescription (wHR=1.77, 95% CI 1.01-3.11), and IVM was only associated with death or ICU transfer (wHR=1.58, 95%CI 1.11-2.25). No effect was found for AZIT or AZIT + IVM.

Conclusion: Our study reported no beneficial effects of hydroxychloroquine, ivermectin, azithromycin, or their combinations. The AZIT+HCQ treatment reported increased risk of all-cause mortality.

Keywords: COVID-19 drug treatment, Hydroxychloroquine, Azithromycin, Ivermectin, Machine Learning, Peru.

INTRODUCTION

The coronavirus disease 2019 (COVID-19) imposed a major global challenge given its rapid transmission worldwide and high mortality among other health and societal consequences (1, 2). None pharmacological treatment have demonstrated effectiveness to control the SARS-CoV-2 infection or improving clinical outcomes, which worsen the current sanitary emergency especially of low-middle income countries (3). Traditionally, any specific drugs to treat the infection might take several years to develop. However, given the rapid spread of the COVID-19 pandemic, and without available drugs against the SARS-CoV-2 virus, several existing drugs were repurposed based on in-vitro studies or low-quality evidence. Consequently, there has been extensive efforts on investigating the efficacy and effectiveness of several pharmacological treatments using randomized clinical trials as well as observational studies (4).

Currently, only dexamethasone has demonstrated benefit to reduce all-cause mortality and requirement of mechanical ventilation; as well remdesivir seems to reduce symptoms duration and occurrence of severe adverse events (5). On the other hand, some emergently repurposed treatments have consistently demonstrated no benefits on all-cause mortality, including hydroxychloroquine with or without azithromycin, lopinavir-ritonavir, and convalescent plasma (5). Ivermectin has only demonstrated efficacy in laboratory conditions, but not evidence has yet reported on hospitalized patients with COVID-19 (6). Most studies tested the efficacy and effectiveness in hospitalized patients to prevent all-cause mortality, serious adverse events, admission to intensive care, need of mechanical ventilation, and receipt of renal replacement therapy; however, many of these studies had limitations that render the evidence low quality. Despite this, these drugs continue to being used in different health systems worldwide, and some of them have even been tested for pre-exposure prophylaxis among healthcare professional finding the same unsuccessful results (7).

Peru has been greatly impacted by the pandemic, by October 5, 2020, it is the sixth country with highest number of reported cases worldwide and mortality rate (828,169 cases and 101.94 deaths per 100,000 inhabitants, respectively) (8, 9). The urgent need to address this national crisis, drove the Peruvian Ministry of Health to authorize the use of hydroxychloroquine with or without azithromycin, oral ivermectin alone or in combination with the other drugs (10, 11). Given the permitted clinical prescriptions in hospitalized patients with COVID-19, and the electronic health records nationwide available in the Peruvian Social Health Insurance (EsSalud), we intended to efficiently use this real-world data to make a robust causal analysis emulating a randomized controlled clinical trial (12, 13).

In this way, the biases traditionally associated with observational studies might be minimized letting obtain more realistic estimates of effectiveness (14). Moreover, we intended to use novel techniques of machine-learning algorithms to improve our propensity score estimation. Thus, our study aimed to evaluate the effectiveness of hydroxychloroquine, azithromycin, and ivermectin alone or combined, to prevent all-cause mortality in hospitalized patients with COVID-19 but without life-threatening illness. Secondarily, we evaluated two composite outcomes, survival without intense care unit (ICU) transfer, and survival without oxygen prescription.

METHODS

Study design and population

We conducted a retrospective cohort study to analyze data obtained from routine care patients hospitalized with COVID-19 which were registered in electronic health records (EHR) in mid- and high-level complexity hospitals from the Peruvian Social Security Health System (EsSalud). We emulated a target trial to obtain robust estimates of clinical effectiveness for hydroxychloroquine/chloroquine, azithromycin, ivermectin, alone or combined, on relevant clinical outcomes (12, 15). We retrieved anonymized data of COVID-19 patients, as defined by the Pan-American Health Organization (16), using the International Classification of Disease Tenth Revision (ICD-10) codes (17).

We included patients admitted between April 1 and July 19, 2020 with the following criteria: 18 years old or above; confirmed SARS-CoV-2 infection by RT-qPCR; clinical manifestations compatible with non-severe disease at admission (no need of oxygen, no diagnosis of acute respiratory failure, systemic inflammatory response syndrome, sepsis or septic shock, acute respiratory distress syndrome [ARDS], acute pulmonary edema, neither disseminated intravascular coagulation [DIC]). We excluded patients with any of these criteria: self-report of pregnancy at admission; discharge, ICU admission or death within 24 hours of admission; received other experimental drugs (tocilizumab, lopinavir-ritonavir or remdesivir) within 48 hours of admission; self-reported treatment of hydroxychloroquine for rheumatological diseases.

Treatment strategies

We compared five treatment groups to the standard of care treatment regimen, as a control group. The treatment groups were defined as follows: hydroxychloroquine/chloroquine alone (HCQ group), ivermectin alone (IVM group), azithromycin alone (AZIT group), hydroxychloroquine/chloroquine

plus azithromycin (HCQ + AZIT group), and ivermectin plus azithromycin (IVM + AZIT group) at doses recommended by the Peruvian Ministry of Health (10, 11). The standard of care was defined as a treatment regimen of antipyretics, hydration, monitorization and basic supportive care. The decision to administer one of these treatment groups depended on clinician's own criteria guided by the Ministry of Health recommendations, which was changing over time according to updated evidence-based reviews (10, 11). Thus, there was an expected heterogeneity of administered treatment to patients across different hospitals, services, and even month of hospitalization.

We allowed a grace period of 48 hours to initiate therapy in order to assess a more realistic clinical question: what is the effectiveness of initiating therapy within 48 hours of hospitalization compared to only receiving standard care within 48 hours of hospitalization? Hence, patients who received any of the treatment regimens after 48 hours of hospitalization were assigned to the control group. Although this approach is similar to an intention-to-treat analysis, the 48 hours period of grace allow us to estimate a per protocol effect as a causal contrast of interest. As mentioned before, patients who developed any of the outcomes within 24 hours of admission were excluded. However, we still included the patients who developed the outcome after 24 hours but before being assigned to a group during the grace period (48 hours). Given that these patients could have potentially been assigned to any group, they were randomly distributed between the control and treatment groups to avoid time-dependent bias due to inappropriate exclusion or treatment assignment (12).

Start, end of follow-up and outcomes

The onset of follow-up or time zero for each patient was the date of hospitalization. The end of the follow-up was the date of occurrence of any outcome (death, death and/or transfer to ICU, death and/or oxygen prescription), discharge, or end of follow-up by July 19, 2020. The primary outcome was all-cause mortality rate, and the secondary outcomes were survival without ICU rate, and survival without oxygen prescription rate.

Strategy for emulating random assignment

In order to emulate the random assignment of a target trial, we used a propensity score weighting for multivalued treatments employing a machine-learning approach letting us calculate balanced differences on the baseline covariates for each control and treatment groups (18, 19). The propensity score estimates the probability of receiving a certain treatment given their baseline or pre-treatment characteristics (20). Under the assumption of positivity and none unmeasured confounding, the propensity score can be used to create weights that allows robust estimations of causal effects in

observational studies (20). Moreover, we used machine-learning algorithm named generalized boosting models (GBM) to estimate propensity scores for treatment assignment (15, 21), and determine the inclusion of baseline covariates and their interactions in the model. GBM fits classification trees using large and non-parsimonious number of pre-treatment covariates. This non-parametric approach improves traditional logistic regression for propensity score estimation (22) because it minimizes bias from model misspecification commonly obtained by incorrect parametric model assumptions (23), and works well with missing data (22). We trained 5000 classification trees setting the following parameters for training: bag fraction of 1, shrinkage factor of 0.01, testing all interactions of all two- and three-covariates (24), and using the minimization of the standardized mean as the stop method of the GBM to select the method with the optimal balance. Moreover, we generated propensity score weights (PSW) using the standardized treatment assignment ratio weighting to estimate the average treatment effect on treated subjects (ATET) (25, 26). This method sets the PSW to 1 for control group (standard of care) and calculates the PSW for treatment groups using the odds in the reference groups (PSW = propensity score/(1-propensity score)) (26).

All the variables included in the propensity score model were selected before the analysis based on expert knowledge about COVID-19. In addition, we selected pre-treatment covariates which could be confounders or prognostically relevant of the outcome (18). We did not include baseline variables theoretically associated with treatment assignment, but not with outcome, to avoid power reduction and/or bias amplification (18, 27). The baseline covariates included were: age; sex; month of admission; location of the health center (Capital, North, South, Center, Rainforest); Charlson's index at hospital admission; comorbidities known in the first 48 hours (myocardial infarct/chronic heart failure/peripheral vascular disease; chronic lung disease; mild/severe liver disease; uncomplicated/complicated diabetes mellitus; cancer, stroke/dementia/paralysis; chronic kidney disease; metabolic disease; peptic ulcer disease; HIV; and uncomplicated/complicated hypertension); emergency care before hospital admission; antibiotics (other than azithromycin) used within 48 hours of admission; previous use of angiotensin-converting enzyme inhibitors/angiotensin-II receptor antagonists; and pneumonia diagnosed within 48 hours of admission. We assessed the overlap of propensity score distributions between the control group and each treatment group to verify the common support assumption. The balance was assessed using standardized mean differences for numerical covariates, and row differences for categorical variables. In all cases, we considered a threshold of 10% as indicative of meaningful imbalance (18). During balance optimization, we remained blinded to the outcome results of the study. Propensity score estimation was performed

using the function *mnps* from the *Twang* package (24), and covariate balance was assessed using *cobalt* (28), both in R version 4.0.2 (29) for MS Windows Pro 10x64 bits.

Statistical analysis

We reported baseline characteristics of the control and treatment groups and 30-days cumulative incidence estimated with the Kaplan-Meier method. Comparisons of time-to-event outcomes between treatment groups was done using weighted Kaplan-Meier survival curves. We estimated unweighted (uHR) and propensity score weighted hazard ratios (wHR) using simple Cox proportional hazards regression to assess effectiveness. To additionally control for residual confounding, we estimated weighted HR with doubly robust adjustment (drwHR) by performing a multivariable and weighted Cox model that conditions for all the baseline covariates used to create the propensity score. Finally, we performed a Bonferroni adjustment of the p-values and the 95% confidence intervals (CI) to compare the treatment groups versus the control group, keeping the type 1 error rate below 5%. All survival analyses were weighted by PSWs in Stata SE version 16.1 for Windows Pro 10 x64 bits (30).

Ethics

This study was classified as minimal risk for participants. To maintain the privacy of the patients, EsSalud's informatics office anonymized all datasets before transfer to researchers. This target trial protocol was approved by EsSalud's Institutional Review Board of COVID studies (91-SGRyGIS-DIS-IETSI-ESSALUD-2020) and was also registered in the Peruvian Health Research Projects repository (PRISA, by its acronym in Spanish) with ID EI-1243 (31).

RESULTS

We included 5683 patients from 72 healthcare centers distributed in 28 health networks at national level. Of whom 200 received hydroxychloroquine or chloroquine within 48 hours of hospital admission, 203 received ivermectin, 1600 received azithromycin, 692 received hydroxychloroquine or chloroquine plus azithromycin, 358 received ivermectin plus azithromycin and 2630 received standard of care (none of the antimicrobials mentioned) (**Figure 1**). The age ranged from 18 to 104 years old with a mean of 59.4 years old (SD = 16.3 years old) and 36.8% (n = 2091) of participants were women. The **Table 1** describes the baseline characteristics of the study population.

Propensity score model development

Propensity scores showed well overlapping in the region of common support between treatment groups versus control group (>95%) (**SM Figure 1**). Before we estimated the inverse probability of treatment weighting, we observed that twelve of 30 baseline covariates had high misbalance (>10% standardized mean difference) across different groups. After we estimated the inverse probability of treatment weighting, only one of the 30 baseline covariates (age) remained imbalanced (>10% standardized mean difference) (**Figure 2**).

Follow-up and outcomes

The median follow-up for overall survival was 7 days (9 days for HCQ, 8 days for IVM, 8 days for AZIT, 9 days for AZIT + HCQ, 8 days for AZIT + IVM). At the end of follow-up, 1072 out of 5683 (18.9%) patients had died (49 [15.3%] in HCQ, 47 [24.5%] in IVM, 325 [23.2%] in AZIT, 165 [23.5%] in AZIT + HCQ, and 85 [23.5%] in AZIT + IVM. **Figure 3** shows weighted KM survival curves for the primary outcome, as well **SM Figure 2** and **SM Figure 3** show weighted KM survival curves for secondary outcomes.

In the non-weighted crude analyses, IVM treatment was associated with higher all-cause mortality and/or ICU transfer hazard rate compared to standard of care (uHR = 1.57; 95%CI 1.16-2.14). AZIT + IVM treatment was associated with 40% higher all-cause mortality hazard rate compared to standard care (uHR = 1.40; 95%CI 1.03-1.90) and also associated with 39% higher all-cause mortality and/or oxygen prescription hazard rate compared with standard care (uHR = 1.39; 95%CI 1.04-1.85). After adjusting by probability of having received of the treatment arms using the inverse probability weighting approach, we observed that AZIT + HCQ was associated with 84% higher all-cause mortality hazard rate compared to standard care (wHR = 1.84; 95%CI 1.12-3.02). Consistently, AZIT + HCQ was associated with higher all-cause mortality and/or ICU transfer hazard rate (wHR = 1.49, 95% CI: 1.01-2.19) and higher all-cause mortality and/or oxygen prescription hazard rate (wHR = 1.70, 95% CI: 1.07-2.69) (see **Table 2**). Except for survival without transfer to ICU, these results were consistent even after doing double-robust adjustment to reduce residual confounding in the sensibility analysis (see **SM Table 1**).

Although we found inconsistent results regarding the estimated effect of HCQ on primary and secondary outcomes, overall, we found results compatible with no effect. The weighted analysis showed that HCQ was associated with 77% higher all-cause mortality and/or oxygen prescription hazard rate compared to standard treatment (wHR = 1.77, 95% CI: 1.01-3.11). The double-robust

adjustment sensitivity analysis showed that HCQ treatment was associated with twice all-mortality hazard rates (drwHR = 2.08, 95% CI: 1.12-3.86) and all-mortality and/or oxygen prescription hazard rates (drwHR = 2.13, 95% CI: 1.20-3.77) compared to standard care. In this sensitivity analysis, we also observed that HCQ group was also associated to higher all-cause mortality and/or ICU transfer hazard rate compared to the control group (drwHR = 1.69, 95% CI: 1.04-2.76).

We observed that IVM treatment was associated with all-cause mortality and/or ICU transfer hazard rate in the weighted analysis (wHR = 1.58, 95% CI:1.11-2.25) but not with the other two outcomes. Surprisingly, this finding persisted in the sensibility analysis (drwHR = 1.60, 95% CI: 1.12-2.27). On the other hand, we did not find effect on all-cause mortality reduction or the composite end-points for neither AZIT group nor AZIT + IVM group in all weighted (**Table 2**) and double-adjusted weighted analyses (**SM Table 1**).

DISCUSSION

This is the first study in Latin America, a region widely impacted by the pandemic, emulating a clinical trial based on observational data comparing different drug treatments for COVID-19. Using a database based on thousands of electronic clinical records, it was possible to replicate conditions of a clinical trial for several drugs prescribed during the pandemic. The electronic clinical records were fully implemented by the Peruvian Social Health Insurance in response to the COVID-19 emergency, yielding a unique opportunity to analyze big data under real-world conditions. This study also employed novel statistical tools to emulate adequate randomization of the patients. Not only a propensity score weighting was used to balance the control and intervention groups according to the probability of having been prescribed a certain drug, but the regression itself employed generalized boosted models based on repeated decision trees. The resulting models for our main outcome, all-cause mortality, and two secondary outcomes, survival without ICU and survival without oxygen requirement, showed no benefit from any of the treatment arms compared with standard care. There was even a consistent increase of risk developing the outcome with the hydroxychloroquine and azithromycin combination.

Azithromycin

Our study showed no effect of azithromycin alone over mortality, survival without ICU, and survival without oxygen requirement. Few published studies have compared azithromycin alone versus standard of care free of hydroxychloroquine or ivermectin. Albani et al in Italy followed a cohort of

1403 patients either receiving azithromycin alone, HCQ alone, the combination of both, or none of them. Using propensity score weighting, they found that azithromycin alone was associated with lower mortality (OR 0.60, 95%CI 0.42-0.85) compared to no treatment. Guerin et al in France (32) compared 34 patients on azithromycin alone with no treatment, finding reduction in days to achieve clinical recovery (12.9 vs 25.8, p=0.015). On the other hand, Geleris et al (33) analyzed a large single-center cohort in NYC using propensity score matching to evaluate HCQ, but also assessed azithromycin alone vs standard of care, finding no benefit for the end point of death and/or ICU transfer (HR 1.03, 95%CI 0.81-1.31). Arshad et al (34) also evaluated azithromycin alone as a secondary aim in their multicenter, retrospective, propensity score matched observational study in USA, finding no effect (HR 1.05, 95%CI 0.68-1.62). Rodiguez-Molinero et al in Spain followed a cohort of 239 patients treated with azithromycin alone (35). They were able to match 29 patients on azithromycin alone with an equal number of controls using multiple clinical and prognosis factors. They found no difference in oxygen saturation/fraction of oxygen at 48h, and a longer time to discharge in the azithromycin group. When using the unmatched whole cohort, they found no difference in any of these outcomes. In summary, the available evidence is still contradictory and mainly based on observational designs.

Hydroxychloroquine alone

We found a slight increase of risk for death and/or oxygen requirement, but not for our primary outcome (death), or for death and/or ICU transfer. This is consistent with the systematic review published by Fiolet et al (36) including 29 articles: three RCTs, one non- randomized trial, and 25 observational studies. They included 11932 patients on the HCQ alone group, 8081 on the HCQ/azithromycin group, and 12930 on the control group. They found no association of HCQ alone with mortality with a pooled relative risk (RR) of 0.83 (95%CI 0.65-1.06) for all 17 studies and RR of 1.09 (95%CI 0.97-1.24) for the three randomized controlled trials. Among these studies, the New England Journal paper by Geleris et al (33), after using propensity score matching, found no significant association between hydroxychloroquine use and intubation or death (HR 1.04, 95%CI 0.82-1.32). Results were similar in multiple sensitivity analyses

Hydroxychloroquine / azithromycin combination

Noticeably, we found a consistent increase on the risk for the three outcomes among the patients who received the HCQ/azithromycin combination compared with standard of care. Similarly, the previously mentioned systematic review by Fiolet et al (36) found that HCQ/azithromycin was associated with an increased mortality (RR = 1.27; 95% CI 1.04-1.54) for six observational studies

plus a RCT. Two other observational studies not included in the previous systematic review, found no benefit in mortality. A Brazilian randomized clinical trial, 447 patients, showed no improvement of clinical outcomes with the use of azithromycin in addition to standard of care that included hydroxychloroquine (OR 1.36, 95%CI 0.94-1.97) in patients with severe COVID-19 (37). Another Brazilian multicenter open-label randomized trial enrolled 504 patients (38). Using a seven-point ordinal scale, they found no difference at 15 days when using either HCQ alone, or in combination with azithromycin. More important, they found more episodes of QT prolongation and liver-enzyme elevation among patients receiving hydroxychloroquine, alone or with azithromycin. An open-label controlled trial in Iran compared 55 patients on HCQ plus lopinavir with 56 patients who received azithromycin on top of that regimen, finding no difference in mortality (39). However, there are at least two big observational studies, which found a beneficial effect of the combination on mortality. Arshad et al in the Henry Ford Health system followed observationally 2561 patients. They found a 66% HR reduction with HCQW and 71% with the HCQ/azithromycin combination (34). Lauriola et al in Italy reported an observational study with 377 consecutive patients and measured in-hospital death. They found a reduce in-hospital mortality with the HCQ/azithromycin combination (HR 0.265, 95%CI 0.17-0.41) (40). Therefore, it is still not clear which is the real effect of the combination based on the published data; however, there is a physio-pathological plausibility that the combination increased cardiac adverse events, affecting survival negatively (41).

Ivermectin

Until the date of this manuscript, there are no published clinical trials or large observational studies analyzing the effect of ivermectin on patients hospitalized with COVID-19. We found no association of ivermectin with all-cause mortality or with death and/or oxygen requirement; however, a deleterious effect was found on death and/or ICU admission. The reason of this association is not immediately clear for us, given the no-effect on the other two outcomes. One possibility is the presence of residual confounding despite the propensity score matching and further model adjustments. We only found pre-printed observational studies evaluating the effectiveness of this drug. The largest series is the ICON study done in Florida, USA (42). They compared 173 patients on ivermectin versus 107 under usual care without employing any matching or weighting. They found less mortality in the ivermectin group (OR 0.52, 95%CI 0.29-0.96) and even greater effect on the subgroup with severe pulmonary disease (OR 0.15, 95%CI 0.05-0.47). A pilot study in Iraq compared 71 patients receiving HCQ/azithromycin with 16 patients receiving a single oral dose of ivermectin on top (43). They found no difference on mortality (2/71 vs 0/16), but less hospitalization time in days (13.2±0.9 vs 7.6±2.8, $p<0.001$). Finally, there is a descriptive study in Argentina with 167

patients and no control group. They evaluated a treatment protocol that includes ivermectin, and reported an overall mortality of 0.59%, lower than their country average (44). Therefore, our study is the largest series assessing the effect of ivermectin among hospitalized patients and employing an adequate comparison between groups.

Limitations and Strengths

Despite being a trial emulation, this study still is an observational retrospective cohort. Without a random assignment, residual confounding by not inclusion of unmeasured confounders is a possibility. To control this, we used a robust approach based on incident users, defining a significant time zero to prevent immortal time-bias, allowing a grace period inclusion and the use of modern data science techniques to emulate random assignment. Especially, the machine learning approach (generalized boosted model) allow us to include many more potential confounders (~30 covariates) in the weighting model, than a conventional logistic regression would allow, without affecting the stability of the propensity scores. This is reflected in the appropriate balance and overlapping achieved between treatment and control groups once the weighting scores were applied. Moreover, a sensitivity analysis was performed using doubly robust adjustment in the weighted Cox regression models, obtaining consistently estimates of causal effects. Despite all these robust strategies, we cannot guarantee that there is some degree of residual confusion in our study. Specifically, our finding that IVM could be associated with an increased risk of one of the secondary outcomes, but not with the rest, could be due to residual confusion not properly controlled even after using the described robust causal inference methods.

Other possible limitation is the occurrence of non-registered variations of the pharmacological treatment, as we relied on electronic records of drug dispensing. This process is strictly monitored and even audited; however, the system does not account for unexpected missing doses. On the other hand, it is important to highlight that our study, like an intention-to-treat approach, allows to estimate the effectiveness (effect in real conditions) of the studied drugs. This approach includes drug discontinuation or regimen modification during hospitalization due to adverse events, poor tolerability, or simply non-adherence. Thus, our results are a good approximation to the effectiveness of these treatments, but they do not necessarily reflect their efficacy (effect under ideal conditions). Although the studied drugs were administered based on the Peruvian Minister of Health guidelines, wide variations between different healthcare centers are expected, thus changing the decision criteria of who to treat. Despite all this, we are confident that our weighting strategy controlled most of the

heterogeneity introduced by inter-hospital disparities; however, some residual confusion is still possible.

Despite these limitations, to the best of our knowledge, this is the first clinical trial emulation done in Latin America for COVID-19, and so far, the largest performed using robust methods to balance groups for emulating random assignment. Also, this is the first study that assess the real-world effectiveness of different treatments commonly used in the Region to treat COVID-19 in hospitalized patients. Different from traditional observational studies, a clinical trial emulation allows for robust design and statistical and machine learning techniques which minimize bias of treatment assignment, yielding reliable results. However, equilibrating control and intervention groups is no easy task, since the most common methods have disadvantages as sample size reduction (matching) or poor overlapping (weighting). The use of machine learning algorithms based on iterative decision trees (boosting) offers an excellent opportunity to optimize the balance between groups, maintaining stable models. Besides, the use of large observational data from electronic health records provides enough power to compare different treatment arms simultaneously, does not require the logistics of a randomized clinical trial, and approximates treatment efficacy under real-world conditions.

Conclusion

The results of this clinical trial emulation match with previous findings of randomized clinical trials and observational studies, which showed no beneficial effects of hydroxychloroquine, ivermectin, azithromycin, or their combinations. Once assignation bias and possible confounders are controlled, the effect of the pharmacological treatments studied is not significant, implying that any effect perceived in observational studies and case series is probably due to confounding effect and selection bias. We even detected a consistent increase in death risk, as well as transfer to ICU and oxygen requirement, with the hydroxychloroquine-azithromycin combination. This association has been reported in other studies and clinical trials, corroborating a potentially harmful effect of this combination. However, we did not have an adequate registry of pharmacological side effects in our electronic database, to suggest adverse reactions as the path for mortality increases.

ACKNOWLEDGMENTS: We thank Engr. Pedro Vasquez, Engr. Elard Pastor and all the team from the EsSalud's informatics office (GCTIC - Gerencia Central de Tecnologías de lnformación y Comunicaciones) for extracting and structuring the anonymized data from the electronic medical records.

REFERENCES

1. Baby K, Maity S, Mehta CH, Suresh A, Nayak UY, Nayak Y. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. Arch Med Res. 2020.
2. Richman DD. Antiviral Drug Discovery To Address the COVID-19 Pandemic. mBio. 2020;11(5):e02134-20.
3. Yu H, Li C, Wang X, Duan J, Yang N, Xie L, et al. Techniques and strategies for the potential protein-targets discovery and active pharmaceutical molecules screening in Pandemic. Journal of Proteome Research. 2020.
4. Sohag AAM, Hannan MA, Rahman S, Hossain M, Hasan M, Khan MK, et al. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. Drug Dev Res. 2020:10.1002/ddr.21709.
5. Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, et al. Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLOS Medicine. 2020;17(9):e1003293.
6. Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. Journal of Cellular Physiology. 2020;n/a(n/a).
7. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA Internal Medicine. 2020.
8. Coronavirus resource center: Johns Hopkins University; 2020 [Available from: https://coronavirus.jhu.edu/map.html.
9. Coronavirus resource center | Mortality: Johns Hopkins University; 2020 [Available from: https://coronavirus.jhu.edu/data/mortality.
10. Prevencion, diagnostico y tratamiento de personas afectadas por COVID-19 en el Peru: Peruvian Ministry of Health; 2020 [Available from: https://www.gob.pe/institucion/minsa/informes-publicaciones/473587-prevencion-diagnostico-y-tratamiento-de-personas-afectadas-por-covid-19-en-el-peru.
11. Manejo ambulatorio de personas afectadas por COVID-19 en el Peru: Peruvian Ministry of Health; 2020 [Available from: https://cdn.www.gob.pe/uploads/document/file/830595/RM_375-2020-MINSA.PDF.
12. Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. American journal of epidemiology. 2016;183(8):758-64.
13. Labrecque JA, Swanson SA. Target trial emulation: teaching epidemiology and beyond. Eur J Epidemiol. 2017;32(6):473-5.
14. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.
15. Lee BK, Lessler J, Stuart EA. Improving propensity score weighting using machine learning. Statistics in medicine. 2010;29(3):337-46.
16. Covid-19 codification with ICD-10: PAHO; 2020 [Available from: https://www.paho.org/arg/index.php?option=com_docman&view=download&alias=468-covid-cie-codigos-2020-03-25-espanol&category_slug=documentos&Itemid=624.
17. EsSI EsSalud's Digital Clinical Records: Peruvian Social Health Insurance; 2020 [Available from: https://essi.pe/.
18. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in medicine. 2015;34(28):3661-79.

19. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Statistics in medicine. 2013;32(19):3388-414.
20. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424.
21. Propensity Score Estimation With Boosted Regression for Evaluating Causal Effects in Observational Studies, (2004).
22. Coffman DL, Zhou J, Cai X. Comparison of methods for handling covariate missingness in propensity score estimation with a binary exposure. BMC medical research methodology. 2020;20(1):168-.
23. Parast L, McCaffrey DF, Burgette LF, de la Guardia FH, Golinelli D, Miles JNV, et al. Optimizing Variance-Bias Trade-off in the TWANG Package for Estimation of Propensity Scores. Health Serv Outcomes Res Methodol. 2017;17(3-4):175-97.
24. Ridgeway G, McCaffrey D, Morral A, Griffin BA, Burgette L, M C. Toolkit for Weighting and Analysis of Nonequivalent Groups (TWANG): CRAN; 2020 [Available from: https://cran.r-project.org/web/packages/twang/.
25. Sato T, Matsuyama Y. Marginal Structural Models as a Tool for Standardization. Epidemiology. 2003;14(6).
26. Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657.
27. Pearl J. Invited Commentary: Understanding Bias Amplification. American Journal of Epidemiology. 2011;174(11):1223-7.
28. Greifer N. Covariate Balance Tables and Plots (cobalt): CRAN; 2020 [Available from: https://cran.r-project.org/web/packages/cobalt/index.html.
29. R Core Team - R: A language and environment for statistical computing: R Foundation for Statistical Computing; 2020 [Available from: https://www.R-project.org/.
30. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC: StataCorp 2019.
31. Soto-Becerra P. Efectividad Clínica Comparativa de Hidroxicloroquina en el Tratamiento de COVID-19 utilizando Datos Observacionales de Registros Clínicos Electrónicos de EsSalud.: PRISA; 2020 [Available from: https://www.ins.gob.pe/prisa/ver_investigacion.aspx?5A53F316-F127-41D6-B894-663E9C8C5E3C.
32. Guérin V, Lévy P, Thomas J-L, Lardenois T, Lacrosse P, Sarrazin E, et al. Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19. AJMAH 18(7):45-5.
33. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England journal of medicine. 2020;382(25):2411-8.
34. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403.
35. Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C, Miñarro A, Macho O, López GF, et al. Observational study of azithromycin in hospitalized patients with COVID-19. PloS one. 2020;15(9):e0238681-e.
36. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020:S1198-743X(20)30505-X.

37. Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. The Lancet. 2020;396(10256):959-67.
38. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. The New England journal of medicine. 2020:NEJMoa2019014.
39. Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. International journal of antimicrobial agents. 2020;56(4):106143-.
40. Lauriola M, Pani A, Ippoliti G, Mortara A, Milighetti S, Mazen M, et al. Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients. Clinical and Translational Science. 2020;n/a(n/a).
41. Alizargar J. Dangers of the Use of hydroxychloroquine and azithromycin combination in COVID-19 patients. Travel medicine and infectious disease. 2020;38:101881-.
42. Rajter JC, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter J-J. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv. 2020:2020.06.06.20124461.
43. Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM, Aljabory AM, et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). medRxiv. 2020:2020.07.07.20145979.
44. Carvallo HE, Hirsch RR, Farinella ME. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv. 2020:2020.09.10.20191619.

Table 1. Baseline characteristics of patients with COVID-19 assigned to one of the treatment groups (HCQ, IVM, AZIT+HCQ and AZIT+IVM) or standard care (control group)

Baselines covariates	Standard care		HCQ		IVM		AZIT		AZIT + HCQ		AZIT + IVM		Total	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Total	2,630		200		203		1,600		692		358		5,683	
Sex														
Female	1,128	42.9	62	31	73	36	493	30.8	220	31.8	115	32.1	2,091	36.8
Male	1,502	57.1	138	69	130	64	1,107	69.2	472	68.2	243	67.9	3,592	63.2
Mean age (SD), years	56.3 (17.2)		59.1 (14.8)		62.9 (15.2)		60.2 (15.4)		59.9 (14.4)		60.0 (15.7)		58.4 (16.3)	
Origin of the health care center														
Capital of Peru	1,402	53.3	111	55.5	66	32.5	864	54	317	45.8	113	31.6	2,873	50.6
East region	144	5.5	14	7	3	1.5	92	5.8	32	4.6	9	2.5	294	5.2
Center region	268	10.2	18	9	33	16.3	286	17.9	160	23.1	130	36.3	895	15.7
North region	434	16.5	25	12.5	72	35.5	222	13.9	92	13.3	91	25.4	936	16.5
South region	382	14.5	32	16	29	14.3	136	8.5	91	13.2	15	4.2	685	12.1
Month														
April	65	2.5	40	20	1	0.5	42	2.6	155	22.4	1	0.3	304	5.3
May	397	15.1	99	49.5	11	5.4	223	13.9	377	54.5	18	5	1,125	19.8
June	1,075	40.9	44	22	100	49.3	735	45.9	117	16.9	180	50.3	2,251	39.6
July	1,093	41.6	17	8.5	91	44.8	600	37.5	43	6.2	159	44.4	2,003	35.2
Emergency stay previous to hospitalization														
No	1,802	68.5	131	65.5	147	72.4	1,234	77.1	443	64	249	69.6	4,006	70.5
Yes	828	31.5	69	34.5	56	27.6	366	22.9	249	36	109	30.4	1,677	29.5
Charlson index														
0	2,416	91.9	190	95.0	190	93.6	1,497	93.6	650	93.9	336	93.9	5,279	92.9
1	125	4.8	7	3.5	10	4.9	79	4.9	31	4.5	18	5.0	270	4.8
2	66	2.5	3	1.5	2	1.0	16	1.0	7	1.0	3	0.8	97	1.7
3	9	0.3	0	0.0	1	0.5	5	0.3	0	0.0	0	0.0	15	0.3
4	9	0.3	0	0.0	0	0.0	1	0.1	4	0.6	1	0.3	15	0.3
5	1	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	2	0.04

6	3	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.05
7	1	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	2	0.04
Obesity														
No	2,522	95.9	188	94	191	94.1	1,534	95.9	648	93.6	345	96.4	5,428	95.5
Yes	108	4.1	12	6	12	5.9	66	4.1	44	6.4	13	3.6	255	4.5
Uncomplicated/complicated hypertension														
No	2,220	84.4	173	86.5	153	75.4	1,364	85.3	587	84.8	293	81.8	4,790	84.3
Yes	410	15.6	27	13.5	50	24.6	236	14.8	105	15.2	65	18.2	893	15.7
Cardiovascular disease														
No	2,593	98.6	199	99.5	200	98.5	1,584	99	689	99.6	354	98.9	5,619	98.9
Yes	37	1.4	1	0.5	3	1.5	16	1	3	0.4	4	1.1	64	1.1
Neurological disorder														
No	2,582	98.2	198	99	195	96.1	1,586	99.1	689	99.6	354	98.9	5,604	98.6
Yes	48	1.8	2	1	8	3.9	14	0.9	3	0.4	4	1.1	79	1.4
Chronic lung disease														
No	2,594	98.6	196	98	199	98	1,572	98.3	676	97.7	349	97.5	5,586	98.3
Yes	36	1.4	4	2	4	2	28	1.8	16	2.3	9	2.5	97	1.7
Mil/severe liver disease														
No	2,604	99	199	99.5	201	99	1,595	99.7	689	99.6	356	99.4	5,644	99.3
Yes	26	1	1	0.5	2	1	5	0.3	3	0.4	2	0.6	39	0.7
Uncomplicated/complicated diabetes mellitus														
No	2,335	88.8	177	88.5	168	82.8	1,397	87.3	613	88.6	314	87.7	5,004	88.1
Yes	295	11.2	23	11.5	35	17.2	203	12.7	79	11.4	44	12.3	679	11.9
Chronic kidney disease														
No	2,498	95	192	96	190	93.6	1,549	96.8	674	97.4	349	97.5	5,452	95.9
Yes	132	5	8	4	13	6.4	51	3.2	18	2.6	9	2.5	231	4.1
Cancer														
No	2,589	98.4	198	99	201	99	1,588	99.3	690	99.7	356	99.4	5,622	98.9
Yes	41	1.6	2	1	2	1	12	0.8	2	0.3	2	0.6	61	1.1

Metabolic disease														
No	2,627	99.9	200	100	203	100	1,599	99.9	692	100	358	100	5,679	99.9
Yes	3	0.1	0	0	0	0	1	0.1	0	0	0	0	4	0.1
Peptic ulcer disease														
No	2,628	99.9	200	100	203	100	1,600	100	692	100	358	100	5,681	100
Yes	2	0.1	0	0	0	0	0	0	0	0	0	0	2	0
HIV														
No	2,621	99.7	200	100	203	100	1,599	99.9	688	99.4	357	99.7	5,668	99.7
Yes	9	0.3	0	0	0	0	1	0.1	4	0.6	1	0.3	15	0.3
Antibiotics use in the first 48 hours after admission														
No	2,303	87.6	180	90	172	84.7	1,357	84.8	604	87.4	316	88.5	4,932	86.8
Yes	325	12.4	20	10	31	15.3	243	15.2	87	12.6	41	11.5	747	13.2
Treatment with ACEI or ARB														
No	2,468	93.9	184	92	196	96.6	1,548	96.8	670	97	341	95.5	5,407	95.2
Yes	160	6.1	16	8	7	3.4	52	3.3	21	3	16	4.5	272	4.8
Corticoid use during first 48 hours														
No	2,399	91.2	182	91	188	92.6	1,455	90.9	641	92.6	341	95.3	5,206	91.6
Yes	231	8.8	18	9	15	7.4	145	9.1	51	7.4	17	4.7	477	8.4
Anticoagulation														
No	2,287	87	173	86.5	182	89.7	1,410	88.1	598	86.4	318	88.8	4,968	87.4
Yes	343	13	27	13.5	21	10.3	190	11.9	94	13.6	40	11.2	715	12.6
Pneumonia diagnosis at first 48 hours														
No	2,186	83.1	143	71.5	159	78.3	1,292	80.8	485	70.1	244	68.2	4,509	79.3
Yes	444	16.9	57	28.5	44	21.7	308	19.3	207	29.9	114	31.8	1,174	20.7

HCQ: Hydroxychloroquine or chloroquine. IVM: ivermectin. AZIT: azithromycin. AZIT + HCQ: azithromycin plus hydroxychloroquine. AZIT + IVM: azithromycin plus ivermectin. ACEI: angiotensin converting enzyme inhibitor. ARB: angiotensin receptor blocker. SD: standard deviation; %: Percentage of column.

Table 2. Primary and secondary outcomes in patients with COVID-19 assigned to treatment groups or standard care (control group)

Outcome	Standard of care	HCQ group	IVM group	AZIT group	AZIT + HCQ group	AZIT + IVM group
All-cause mortality						
Nº of events / Total	401/2630	49/200	47/203	325/1600	165/692	85/358
30-days Cumulative Incidence (%)*	42.6 (37.5-48.2)	49.7 (33.1-69.1)	51.4 (35.2-69.9)	50.3 (43.5-57.6)	48.7 (40.1-58.2)	47.2 (37.0-58.6)
uHR (95% CI)	1.00 (Ref)	1.39 (0.94-2.05)	1.40 (0.94-2.08)	1.13 (0.94-1.37)	1.20 (0.95-1.53)	**1.40 (1.03-1.90)**
wHR (95% CI)**	1.00 (Ref)	1.73 (0.94-3.17)	1.39 (0.88-2.22)	1.15 (0.94-1.40)	**1.84 (1.12-3.02)**	1.37 (0.91-2.05)
Survival without transfer to ICU						
Nº of events / Total	652/2630	71/200	79/203	481/1600	237/692	122/358
30-days Cumulative Incidence*	51.3 (45.1-57.9)	65.6 (43.8-86.1)	58.7 (42.5-75.5)	54.3 (47.2-61.8)	54.4 (47-62.2)	55.7 (45.9-66.0)
uHR (95% CI)**	1.00 (Ref)	1.29 (0.93-1.78)	**1.57 (1.16-2.14)**	1.06 (0.91-1.23)	1.13 (0.93-1.37)	1.24 (0.96-1.59)
wHR (95% CI)	1.00 (Ref)	1.55 (0.96-2.49)	**1.58 (1.11-2.25)**	1.08 (0.92-1.27)	**1.49 (1.01-2.19)**	1.28 (0.94-1.76)
Survival without need for oxygen						
Nº of events / Total	494/2630	59/200	52/203	414/1600	198/692	101/358
30-days Cumulative Incidence*	48.5 (43.1-54.2)	55.2 (37.8-74.3)	58.7 (42-76.1)	57.8 (50.8-65)	54.3 (45.4-63.6)	51.7 (41.5-62.8)
uHR (95% CI)	1.00 (Ref)	1.47 (1.03-2.10)	1.29 (0.88-1.88)	1.17 (0.98-1.40)	1.23 (0.98-1.53)	**1.39 (1.04-1.85)**
wHR (95% CI)**	1.00 (Ref)	**1.77 (1.01-3.11)**	1.21 (0.77-1.90)	1.17 (0.97-1.41)	**1.70 (1.07-2.69)**	1.21 (0.82-1.80)

uHR = unweighted hazard ratio; wHR = weighted hazard ratio; 95% CI = 95% confidence interval.

* Cumulative incidence and 95% confidence intervals were obtained by Kaplan Meier life table method to account by censors.

** Weighted hazard ratios and 95% confidence intervals were obtained by inverse probability treatment weighting. A gradient boosting machine was trained to estimate each patient's probability of receiving treatments given their baseline probabilities. Baselines covariates used to train the GBM were age, sex, Charlson's index at hospital admission, comorbidities registered in the first 48 hours (myocardial infarct/chronic heart failure/peripheral vascular disease, stroke, chronic lung disease, mild/severe liver disease, uncomplicated/complicated diabetes mellitus, cancer, stroke/dementia/paralysis, chronic kidney disease, metabolic disease, peptic ulcer disease, HIV, uncomplicated/complicated hypertension, healthcare network, month, history of emergency care before hospital admission, antibiotics used (other than azithromycin) in the first 48 hours, antecedent of angiotensin-converting enzyme inhibitors/angiotensin-II receptor antagonists, and pneumonia diagnosis in the first 48 hours.

Figure 1. Study flowchart



Figure 2. Balance plot of the standardized differences of baseline covariates used to estimate the propensity score (n = 5683)



Figure 3. Weighted Kaplan-Meier curves for overall survival between each group of treatment versus standard care (control group)